568 related articles for article (PubMed ID: 37095712)
1. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C
Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984
[TBL] [Abstract][Full Text] [Related]
4. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
[TBL] [Abstract][Full Text] [Related]
5. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
[TBL] [Abstract][Full Text] [Related]
6. [Impact of different types of heart failure on long-term renal prognosis in patients with renal insufficiency and heart failure].
Wang YC; Ye N; Bian WJ; Cheng H
Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 39(1):1-7. PubMed ID: 36776008
[No Abstract] [Full Text] [Related]
7. The midrange left ventricular ejection fraction (LVEF) is associated with higher all-cause mortality during the 1-year follow-up compared to preserved LVEF among real-world patients with acute heart failure: a single-center propensity score-matched analysis.
Borovac JA; Novak K; Bozic J; Glavas D
Heart Vessels; 2019 Feb; 34(2):268-278. PubMed ID: 30159656
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
10. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
[TBL] [Abstract][Full Text] [Related]
11. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
12. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
14. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
[TBL] [Abstract][Full Text] [Related]
15. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
[TBL] [Abstract][Full Text] [Related]
16. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
[TBL] [Abstract][Full Text] [Related]
17. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
18. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
[TBL] [Abstract][Full Text] [Related]
20. Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk.
Miller RJH; Nabipoor M; Youngson E; Kotrri G; Fine NM; Howlett JG; Paterson ID; Ezekowitz J; McAlister FA
ESC Heart Fail; 2022 Jun; 9(3):1564-1573. PubMed ID: 35261203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
